Type 1 diabetes: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 21
• SGLT2 12
• NRF2 0
• CTLA-4 0
• STAT3 0
• AKT 0
• GIP 2
• PD-1 0
• SIRT1 0
• CD40 0
• PPAR 0
• TP53 0
• JAK 1
• JNK 0
• mTOR 0
• NLRP3 1
• TLR4 0
• AMPK 0
• DPP-4 0
• IL-6 0
• TNF 0
• IL-1 0
• IL-17 0
• MAPK 0
• PI3K 0
• VEGF 1
• CD47 0
• HMGB1 0
• PD-L1 0
• ACE2 0
• BDNF 0
• CD19 0
• CD20 1
• CD38 0
• ERK 0
• FOXP3 0
• G6PD 0
• IL-13 0
• IL-4 0
• PCSK9 0
• RANKL 0
• STING 0
• TIGIT 0
• AR 0
• B7-H3 0
• CD22 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• GPX4 0
• HDAC 0
• HER2 0
• HER3 0
• HSP90 0
• IGF1R 0
• LAG-3 0
• METTL3 0
• MYC 0
• NMDA 0
• PDGFR 0

24 of 1,965 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Modeling islet inflammation in early-stage type 1 diabetes: T1DstartEd (T1Dstarted)

  The Hebrew University of Jerusalem· Jerusalem, Israel· EU contribution €2,796,250· until May 2032

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  The Inreda bi-hormonal blood glucose control pump: A beacon for high-risk diabetes patients, providing fully automated in disease management (DIABEACON)

  Inreda Diabetic Bv· Goor, Netherlands· EU contribution €2,499,414· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Type 1 Diabetes Simulator with Adjunctive therapies - GLP1 (T1SIA)

  Universitat Politecnica de Valencia· Valencia, Spain· EU contribution €243,097· until Jan 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  From harassing to harnessing beta-cells in type 1 diabetes (Beta-STEALTH)

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €2,500,000· until Oct 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Uncovering Protective Mechanisms in Pancreatic β-Cells to Enhance Their Survival in Type 1 Diabetes (Beta_cell_protection)

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €200,400· until Jul 2027

5 of 9 running projects, newest first. Listed amounts together: €48.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Siplizumab in T1DM

  NCT05574335· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 13 Nov 2026

  “Prior to termination the DESIGNATE study was an on enrollment hold due to greater than anticipated lymphodepletion. The pharmaceutical partner decided not to reopen its own T1D trial and ceased development of siplizumab in autoimmunity.”Registry text, quoted unchanged. Source

• Withdrawn

  Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment

  NCT04177303· Hellenic Institute for the Study of Sepsis· Updated 3 Nov 2026

  “It was not conducted due to the emergency restrictive measures implemented during the COVID-19 pandemic, which made it impossible to carry out the patient visits required by the study protocol.”Registry text, quoted unchanged. Source

• Terminated

  Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes

  NCT06854861· St. Olavs Hospital· Updated 19 Oct 2026

  “The study was terminated due toa combination of: 1. At best minimal effect on insulin absorption 2. Withdrawal of funding as the patent application for using glucagon to enhance subcutaneous insulin absorption was not approved.”Registry text, quoted unchanged. Source

• Terminated

  Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients With Type 1 Diabetes (T1D)

  NCT06315725· McGill University Health Centre/Research Institute of the McGill University Health Centre· Updated 6 Oct 2026

  “The study was terminated due to recruitment difficulties. Only three participants enrolled within two years due to specific insulin pump requirements. Recruitment was therefore discontinued before the planned sample size was reached.”Registry text, quoted unchanged. Source

• Withdrawn

  Clinican BEAD-T1D: Building the Evidence to Address Disengagement in Type 1 Diabetes

  NCT07491471· Stanford University· Updated 24 Sept 2026

  “Change in research priority”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Suspended

  Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in Kenya.

  NCT05944731· Foundation for Innovative New Diagnostics, Switzerland· Updated 21 Sept 2026

  “funding issues”Registry text, quoted unchanged. Source

• Terminated

  Effects of HBO on Glucose in Patients With DM

  NCT04261738· Legacy Health System· Updated 26 Aug 2026

  “Facility closure, awaiting relocation”Registry text, quoted unchanged. Source

• Withdrawn

  Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus

  NCT05985135· Mayo Clinic· Updated 5 Aug 2026

  “Changed IRB number”Registry text, quoted unchanged. Source

• Terminated

  Societal Burden Associated With Type 1 Diabetes in Canada

  NCT06786130· PeriPharm· Updated 30 Jul 2026

  “Recruitment.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Siplizumab in T1DM

  NCT05574335· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

  NCT07088068· Sanofi· Source

• Can Mindfulness and Virtual Reality Reduce Stress in Young Adults With Type 1 Diabetes?

  NCT07793097· Wayne State University· Source

• Thrive With Type 1 Diabetes 2026

  NCT07522866· Emory University· Source

• A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

  NCT04929379· Alessandro Doria· Source

• Effect of a Probiotic Supplement on Gut Microbiota and Glycemic Control in Patients With Type 1 Diabetes (PRODIAB)

  NCT07062224· Universidad Católica San Antonio de Murcia· Source

• One-Minute Exercise Snacks and Daytime Glucose in Adults With Type 2 Diabetes

  NCT07930065· Capital University of Physical Education and Sports, China· Source

• A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes

  NCT07896109· Novo Nordisk A/S· Source

• A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

  NCT07776509· AstraZeneca· Source

• Long-Term Outcomes of Teplizumab in Routine Clinical Care

  NCT07360080· Sanofi· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 10
• Organoids 4
• Mendelian Randomization Analysis 35
• CRISPR-Cas Systems 5
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 12
• Immunohistochemistry 16
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 33
• Machine Learning 31
• Deep Learning 10
• Cohort Studies 158
• Genome-Wide Association Study 54

• Immunometabolic interactions of Leishmania infantum lysate- adsorbed aluminum hydroxide nanoparticles in streptozotocin-induced diabetic rats.

  Microb Pathog, Aug 2026

• In Vivo Imaging of the Innate Immune System in the Pancreas in New-Onset and Long-Standing Type 1 Diabetes.

  Diabetes Obes Metab, Mar 2026

• Effect of pravastatin on low-density lipoprotein oxidation and myocardial perfusion in young adults with type 1 diabetes.

  Arterioscler Thromb Vasc Biol, May 2004

See which targets of this disease your abstract mentions, and go to the people working on them.